Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SOT102 |
| Trade Name | |
| Synonyms | SOT-102|SOT 102|SO N102|SO-N102|SON102 |
| Drug Descriptions |
SOT102 is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2)-targeted antibody linked to a derivative of the cytotoxic anthracycline PNU-159682, which potentially leads to impaired DNA replication and protein synthesis, resulting in killing of tumor cells expressing CLDN18.2 (NCI Drug Dictionary). |
| DrugClasses | CLDN18.2 Antibody 23 |
| CAS Registry Number | NA |
| NCIT ID | C190788 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + SOT102 | Fluorouracil Leucovorin Nivolumab Oxaliplatin SOT102 | 0 | 1 |
| Gemcitabine + Nab-paclitaxel + SOT102 | Gemcitabine Nab-paclitaxel SOT102 | 0 | 1 |
| SOT102 | SOT102 | 0 | 1 |